About a year ago, I stuffed all my earthly belongings into my black Volkswagen Jetta and set out on a 10-hour interstate journey. I had just graduated from residency at the University of Kentucky and was headed westward, to Iowa City, for a fresh start as a rheumatology fellow. During the 10 hours I spent…
NEW YORK (Reuters Health)—The American Board of Internal Medicine (ABIM) maintenance-of-certification (MOC) program could cost $5.7 billion in physicians’ time and fees over the next decade, according to a new model study. “We estimate that physicians will spend 33 million hours over 10 years to fulfill MOC requirements,” Dr. Dhruv S. Kazi from the University…
Arthritis Center Renamed to Honor Ephraim P. Engleman, MD Ephraim P. Engleman, MD, has been on the faculty at the University of California, San Francisco (UCSF) since 1947, 10 years after he received his MD from Columbia University. The 104-year-old rheumatologist is currently the director of the Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, which…
CHICAGO—With the approval of the Jak inhibitors (i.e., jakinibs) tofacitinib and ruxolitinib—and others being investigated—rheumatologists need to arm themselves with an understanding of these drugs so they can think critically when evaluating them and deciding how to use them, said John O’Shea, MD, chief of the Molecular Immunology and Inflammation Branch of and scientific director…
CHICAGO—Stem cell transplantation for systemic sclerosis patients has come a long way over the past decade, with more finely calibrated dosing and better patient selection, said George Georges, MD, associate member of the Fred Hutchinson Cancer Research Center and associate professor in the medical oncology division at the University of Washington School of Medicine, Seattle,…
CHICAGO—Scleroderma patients with pulmonary arterial hypertension (PAH) might benefit from more aggressive therapy, an expert in the field said in a session on lung involvement in rheumatic diseases at the American College of Rheumatology’s 2015 State-of-the-Art Clinical Symposium in May. Newer trials—the SERAPHIN trial on macitentan, GRIPHON on selexipag, and AMBITION on an ambrisentan/tadalafil combination—show…
The annual ACR State-of-the-Art (SOTA) Clinical Symposium came highly endorsed by previous fellows; therefore, upon receiving the invitation for the Fellows-in-Training (FIT) scholarship, I did not hesitate to apply. Further, the meeting was going to be held in the spring in Chi Town! Meticulously, I made arrangements with six hundred scholarship dollars at my disposal….
On July 1, 2015, the Rheumatology Research Foundation awarded more than 80 grants to a wide range of rheumatology trainees and professionals. The recipients, who submitted applications in 2014, will receive funding for essential education and training, as well as innovative research projects. Their applications were closely examined by experts in different areas of the…
There are many reasons why 15,000-plus attendees come to the ACR/ARHP Annual Meeting. For some, it’s the more than 450 educational sessions designed to boost knowledge and provide the latest information in the field of rheumatology. For others, it’s the opportunities to build connections and network with colleagues from around the world. This year’s six-day…
The American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals (ARHP) invite you to submit an abstract and take advantage of the opportunity to have your work peer reviewed by experts in rheumatology. Reasons to Submit Opportunity for Publication—The Annual Meeting draws thousands of abstracts submitted by rheumatology professionals from around the…